Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke

A Comparison of Safety and Efficacy of Dl-3-n-butylphthalide and Cerebrolysin on Neurological and Behavioral Outcomes in Acute Ischemic Stroke: a Randomized, Double-blind Study.

The investigators conducted a randomized, double-blind, trial enrolled 60 patients within 12 hours of acute ischemic stroke (AIS) in China. Patients were randomly assigned to receive a 10-day infusion of dl-3-n-butylphthalide (NBP) or cerebrolysin, or placebo. National Institutes of Health Stroke Scale (NIHSS) and Barthel Index (BI) were used to evaluate the efficacy in the patients with AIS at 11-day and 21-day after therapy. Adverse events were also analyzed among the three groups.

Inclusion Criteria:

• Acute ischemic stroke within 12 hours for the first time before entry into the study
• National Institutes of Health Stroke Scale (NIHSS) score between 6 and 25

Exclusion Criteria:

• with lacunar infarction
• with cerebral hemorrhagic infarction
• with epilepsy or epileptic persons
• with history of neurological diseases
• with myocardial infarction,
• with renal and hepatic abnormalities
• with metabolic diseases
• with contraindications to antiplatelet treatments